Literature DB >> 1601015

Immunosuppressive treatment for juvenile myasthenia gravis.

B Badurska1, B Ryniewicz, H Strugalska.   

Abstract

The result of immunosuppressive treatment in 20 cases of generalized myasthenia gravis with onset before age 16 were analysed. The patients age at the beginning of immunosuppressive treatment ranged from 10 to 22 years. Thirteen patients suffered from a severe form of myasthenia gravis with respiratory attacks, the remaining 7 demonstrated a moderately severe form with bulbar symptoms dominating the clinical picture. Indication for immunosuppressive treatment was lack of or only slight improvement after thymectomy. Prednisone was used in 17 cases, high dosage of methylprednisolone in 8 (in one case twice), azathioprine in 11 and cyclophosphamide in 10. Best results were obtained with cyclophosphamide since significant improvement was recorded in 14/20 of patients. Corticosteroids, i.e. prednisone and high-dose methylprednisolone proved to be of limited value.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601015     DOI: 10.1007/bf01954388

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  16 in total

1.  Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients.

Authors:  J G MILLICHAP; P R DODGE
Journal:  Neurology       Date:  1960-11       Impact factor: 9.910

2.  Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.

Authors:  R Hohlfeld; M Michels; K Heininger; U Besinger; K V Toyka
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

3.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

4.  Myasthenia gravis in children: long-term follow-up.

Authors:  M Rodriguez; M R Gomez; F M Howard; W F Taylor
Journal:  Ann Neurol       Date:  1983-05       Impact factor: 10.422

5.  Juvenile myasthenia gravis.

Authors:  O C Snead; J W Benton; D Dwyer; B J Morley; G E Kemp; R J Bradley; S J Oh
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

6.  Stable remissions in myasthenia gravis.

Authors:  M C Perez; W L Buot; C Mercado-Danguilan; Z G Bagabaldo; L D Renales
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

7.  Thymectomy for myasthenia gravis in children.

Authors:  S Youssef
Journal:  J Pediatr Surg       Date:  1983-10       Impact factor: 2.545

8.  Azathioprine toxicity in neuromuscular disease.

Authors:  J T Kissel; R J Levy; J R Mendell; R C Griggs
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

9.  Adverse interaction between steroid hormones and anticholinesterase drugs.

Authors:  B M Patten; K L Oliver; W K Engel
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

10.  [Myasthenia in children: long-term course].

Authors:  H Descamps; J Bataille; B Estournet; A Barois
Journal:  Ann Med Interne (Paris)       Date:  1987
View more
  1 in total

Review 1.  Juvenile myasthenia: diagnosis and treatment.

Authors:  B Anlar
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.